JP2013544244A5 - - Google Patents

Download PDF

Info

Publication number
JP2013544244A5
JP2013544244A5 JP2013539093A JP2013539093A JP2013544244A5 JP 2013544244 A5 JP2013544244 A5 JP 2013544244A5 JP 2013539093 A JP2013539093 A JP 2013539093A JP 2013539093 A JP2013539093 A JP 2013539093A JP 2013544244 A5 JP2013544244 A5 JP 2013544244A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
interleukin
inflammation
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013539093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544244A (ja
Filing date
Publication date
Priority claimed from CN201010551433.8A external-priority patent/CN102462837B/zh
Application filed filed Critical
Publication of JP2013544244A publication Critical patent/JP2013544244A/ja
Publication of JP2013544244A5 publication Critical patent/JP2013544244A5/ja
Pending legal-status Critical Current

Links

JP2013539093A 2010-11-19 2011-11-09 抗炎症組成物 Pending JP2013544244A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010551433.8A CN102462837B (zh) 2010-11-19 2010-11-19 抗炎组合物
CN201010551433.8 2010-11-19
PCT/AU2011/001446 WO2012065212A1 (en) 2010-11-19 2011-11-09 Anti-inflammatory compositions

Publications (2)

Publication Number Publication Date
JP2013544244A JP2013544244A (ja) 2013-12-12
JP2013544244A5 true JP2013544244A5 (https=) 2014-12-25

Family

ID=46067145

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013539093A Pending JP2013544244A (ja) 2010-11-19 2011-11-09 抗炎症組成物

Country Status (12)

Country Link
US (1) US9289493B2 (https=)
EP (1) EP2640411B1 (https=)
JP (1) JP2013544244A (https=)
KR (1) KR101989201B1 (https=)
CN (1) CN102462837B (https=)
AU (1) AU2011331901B2 (https=)
CA (1) CA2817996C (https=)
DK (1) DK2640411T3 (https=)
MX (1) MX348794B (https=)
MY (1) MY174797A (https=)
RU (1) RU2627451C9 (https=)
WO (1) WO2012065212A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013023151A2 (pt) 2011-03-11 2020-09-15 Assistance Publique - Hôpitaux De Paris interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado
DK2683395T3 (en) * 2011-03-11 2018-11-19 Hopitaux Paris Assist Publique USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES
NL2009794C2 (nl) 2012-11-13 2014-05-14 Hevorma B V Groei-inrichting voor gewas, gebruik van een dergelijke inrichting, en een reeks groei-inrichtingen.
AU2015301936B2 (en) 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
KR102731877B1 (ko) * 2015-02-25 2024-11-21 아웃센스 다이아그나스틱스 엘티디. 신체 배출물 분석
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN109963559A (zh) * 2016-09-15 2019-07-02 皮肤科技生命科学有限公司 舌下或颊部施用dim以治疗皮肤病
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
CN118271419A (zh) 2020-03-31 2024-07-02 韩美药品株式会社 新型免疫刺激il-2类似物
US12098178B2 (en) 2020-12-04 2024-09-24 Visterra, Inc. Methods of using interleukin-2 agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU610083B2 (en) * 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
ATE113469T1 (de) * 1990-06-21 1994-11-15 Edith Dr Huland Verwendung zytokinhaltiger aerosole und zytokinhaltige aerosole selbst.
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
US7361331B2 (en) * 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
JP4023863B2 (ja) 1997-03-13 2007-12-19 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ Il−6を含む血清尿酸値低下剤
FR2769505B1 (fr) * 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
WO2000037096A2 (en) * 1998-12-22 2000-06-29 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10
AU780163B2 (en) 1999-09-09 2005-03-03 Merck Sharp & Dohme Corp. Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
WO2004024125A1 (en) 2002-09-16 2004-03-25 Wyeth Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
GB0501540D0 (en) * 2005-01-25 2005-03-02 Univ Leeds Controlled production and delivery of biologically active agents by gut bacteria
AU2008226337B2 (en) 2007-03-14 2012-02-16 BioLingus IP II GmbH Method for treating cancer via the mucosal administration of interleukin
CN102174111B (zh) * 2011-01-25 2013-01-09 江苏省弗泰生物科技有限公司 人白介素2-Fc融合蛋白及其用途

Similar Documents

Publication Publication Date Title
JP2013544244A5 (https=)
RU2013127793A (ru) Противовоспалительные композиции
Jacques et al. The role of IL‐1 and IL‐1Ra in joint inflammation and cartilage degradation
JP2016523862A5 (https=)
EP2011487A3 (en) Pharmaceutical compositions for gastroinetestinal drug delivery
JP2015129189A5 (https=)
JP2014526503A5 (https=)
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
JP2013510123A5 (https=)
Lee et al. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial
CN102014868B (zh) 含有棕榈酰乙醇酰胺和硬脂酰乙醇酰胺的药物制剂
AR095372A1 (es) Terapia de inducción con rituximab seguida por una terapia con acetato de glatiramer
JP2018505158A5 (https=)
JP2014523906A5 (https=)
EP2683372A1 (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
JP2009544690A5 (https=)
JP2022504181A5 (https=)
JP2011157375A5 (https=)
MA38169B2 (fr) Ciclésonide pour le traitement d'une maladie des voies respiratoires chez les chevaux
JP2007119497A5 (https=)
JP2010500284A5 (https=)
JP2005512946A5 (https=)
Li et al. Obesity: Next game changer of allergic airway diseases?
JP2008516909A5 (https=)
JP2012530755A5 (https=)